Rock Creek Pharmaceuticals, Inc. announced that it has filed a Clinical Trial Application (CTA) with the United Kingdom'sMedicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical trials for the continued development of its lead molecule, Anatabine Citrate. Contingent on the Company receiving CTA regulatory approval, the Company plans to conduct a Phase I trial to assess the safety, tolerability and dose escalation of Anatabine Citrate with Quotient Clinical, a UK based, contract research organization (CRO). Quotient Clinical will employ its RapidFACTTM (Rapid Formulation development And Clinical Testing) service to test novel, oral, modified release Anatabine Citrate formulations which have been developed jointly with Rock Creek Pharmaceuticals.